How many investments has BOLD Longevity made?

BOLD Longevity has 12 tracked investments, 1 of which have exited.

What stage does BOLD Longevity invest at?

BOLD Longevity invests at the Growth, Late Stage stages.

What sectors does BOLD Longevity focus on?

BOLD Longevity focuses on AI & Machine Learning, Biotech, Healthtech, Longevity.

Where is BOLD Longevity located?

BOLD Longevity is headquartered in Boston, US.

Does BOLD Longevity lead rounds?

BOLD Longevity typically participates in rounds rather than leading them.

Who does BOLD Longevity co-invest with?

BOLD Longevity most often shares deals with Bold Capital Partners, B Capital Group, Draper Associates, among 87 tracked co-investors.

BOLD Longevity

Growth equityActively deployingoperating company · company profile

Boston · Growth–Late Stage · 10 people tracked

Also known as BLG ADVISOR LLC

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into BOLD Longevity

5,211 people in our graph share verified history with the BOLD Longevity team — schools, employers, funds. One of them is your warm intro.

David Phuunlockedknows Avik Arakelian · together at PwC (overlapped)

×3knows the team · via PwC

×3knows the team · via Morgan Stanley

×3knows the team · via Stanford University

knows the team · via McKinsey & Company

knows the team · via Massachusetts Institute of Technology

✨ Fox Verdict

Investment thesis

BOLD Longevity Growth focuses on growth- and scaling-stage biotechnology companies that target the root causes of aging and age-related diseases. It backs platform technologies delivering large efficiency and safety improvements (5-10x) that reshape medical practice and make treatments more affordable and accessible. The fund co-invests alongside major biotech VC funds and large pharmaceutical companies, contributing capital, experienced partners, and a network of scientific and venture advisors. Its aim is to support companies changing how medicine is practiced and how diseases are diagnosed and treated, enabling healthy human life extension across areas such as gene editing, AI-driven drug discovery, and AI-powered diagnostics.

Invests inAI & Machine Learning Biotech Healthtech Longevity Boston Global United States

Source: firm website, verified Aug 18, 2026.

Stage

Growth–Late Stage

Boston, Massachusetts, US

Leads rounds

Follows

Instruments

Equity

Founded

2023

Private fund assets

$71.3M

VC funds

Tracked investments

Unicorns

IPOs

Team · 10 people

from the firm's website & public directories

Peter Diamandis· Co-Founder & Partner· Santa Monica, Californiain 𝕏

Peter H. Diamandis, MD is a physician, entrepreneur, and futurist who has founded or co-founded more than 25 companies across health, space, education, artificial intelligence, and venture capital. He is the founder of the XPRIZE Foundation and Abundance360, and co-founder of Link-XPV, BOLD Capital Partners, and Fountain Life. Through BOLD Capital Partners, he invests in early-stage and growth technology companies led by entrepreneurs using exponential technologies to address humanity's grand challenges. He is a New York Times bestselling author of books including Abundance, Bold, and The Future is Faster Than You Think, and hosts the MOONSHOTS podcast.

Sergey Young· Co-Founder· Abu Dhabi, Abu Dhabi Emirate, United Arab Emiratesin 𝕏

Sergey Young is a longevity investor with over 20 years of investment experience, backing startups at the intersection of AI, longevity, and biotechnology. He co-founded the BOLD Longevity Growth (BLG) fund, focused on making longevity innovations more accessible and affordable. He co-created and sponsored XPRIZE Healthspan, a $101M competition on reversing human aging, and authored the bestselling book "The Science and Technology of Growing Young." He holds a diploma in Business Administration from Warwick Business School and degrees in Chemical Engineering and Economics.

s•••@blg.vcreveal

Teymour Boutros-Ghali· Co-Founder & Managing Partner· Santa Monica, California, United Statesin

A co-founder and managing partner at BOLD with over 30 years of investing and entrepreneurial experience. Previously a GP at Monitor Ventures and VP at Time Inc. Ventures, he led three companies through acquisitions. He holds a Cambridge EE degree and an MIT PhD.

Avetik Arakelian· General Partner

Avik Arakelian· Partner & Head of Investments· United Statesin

Brings 10+ years of PE and VC investment experience in biotech and health tech, having led or advised investments in more than 25 biotech and longevity companies spanning gene editing, AI drug discovery, and diagnostics. Previously worked at PwC and KPMG.

a•••@blg.vcreveal

Kris Verburgh· Partner & Head of Science· London, England, United Kingdomin

A medical doctor, author and researcher specialized in aging and longevity who authored the bestselling 'The Longevity Code' and created the field of nutrigerontology. He is a researcher at the ECCO Institute at the Free University Brussels.

k•••@blg.vcreveal

Will Borthwick· Principal, BOLD Capital· Los Angeles Metropolitan Areain

A principal at BOLD Capital with 10+ years of experience in investment banking, private equity and venture capital, having worked at Marlin Equity Partners and Morgan Stanley. His expertise spans AI/ML, clinical trial optimization and diagnostics.

Gunner Hardy· Senior Associate· New York, New York, United Statesin

An investment professional with experience in banking, startup advisory and genetics research. He previously worked at BofA Merrill Lynch, the World Bank and EBRD, was an analyst at Conscience VC, and worked with VITA DAO.

g•••@blg.vcreveal

Helen McBride· Operating Partner, BOLD Capital· Los Angeles Metropolitan Areain

Brings 20+ years in healthcare and life sciences, including 13+ years at Amgen and a role at TORL Biotherapeutics. She previously led healthcare investing at Fund@Caltech and holds a PhD in Oncological Sciences.

Sun Altbach· Senior Scientific Advisor· Boston, Massachusetts, United Statesin

A biopharmaceutical executive with over 25 years of experience, having worked at Biogen, Genzyme and Shire, and served as founding CEO of PIC Therapeutics. She holds a BA from Smith College and an MBA from MIT.

Founder mafia

4 people who came through BOLD Longevity went on to found or lead other companies.

Peter DiamandisCo-Founder & PartnerFounded Celularity +1 Teymour Boutros-GhaliCo-Founder & Managing PartnerFounded Allbusiness Kris VerburghPartner & Head of ScienceFounded NOVOS Sun AltbachSenior Scientific AdvisorFounded Pic Therapeutics

What they invest in

from 11 of 12 portfolio companies

Healthtech ×7AI & Machine Learning ×6Biotech ×5Digital Health ×4Deep Tech ×3Medical Devices ×3Hardware ×2Longevity ×1

HQs:United States×9

Who they back

founder profiles across 11 portfolio companies

27%

solo founders

3 of 11 mapped founding teams

50%

repeat founders

of 18 founders with career history

Founding team size:solo founder×32 founders×53 founders×14+ founders×2

Where their founders studiedfrom 13 founders with education data

Massachusetts Institute of Technology ×2Stanford University ×2University of Cambridge ×2University of Washington ×2

What their founders studiedfrom 16 founders with field-of-study data

Computer Science ×6Life Sciences ×6Engineering ×4Medicine ×3Business & Management ×2Humanities ×2Mathematics & Statistics ×2

Where their founders worked beforefrom 18 founders with career history

Insilico Medicine ×2

Investments · 12 tracked

founders shown can be your intro path

4D Molecular Therapeutics4dmoleculartherapeutics.com inNASDAQ: FDMT

4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.

BiotechHealthtechEmeryville, US

David Kirn(Executive Officer, Director)in David Schaffer(Director)inTheresa Janke(Executive Officer)in

BoardSharon Tetlow(Director)Margi McLoughlin(Director)

Co-investorsAmzak Health Berkeley Catalyst Chiesi Ventures Pappas Capital Pfizer Venture Investments Biotechnology Value Fund +3 more

Aqtualaqtual.com in

Aqtual is a precision medicine company led by experienced healthcare professionals, entrepreneurs, and technical experts.

AI & Machine LearningHealthtechMedical DevicesHayward, US

Diana Abdueva(Founder)inRichard Rava(Founder)

Co-investorsBold Capital Partners Genoa Ventures Manta Ray Ventures

BigHat Biosciencesbighatbio.com in 𝕏

Big Hat Bio develops therapeutics under development across multiple programs.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Peyton Greenside(Executive Officer, Director)in Mark DePristo(Executive Officer, Director)in

Board Francisco Gimenez(Director)inSteve Kafka(Director)Vineeta Agarwala(Director)inRobert Chess(Director)

Co-investors8VC Andreessen Horowitz Flucas Ventures GRIDS Capital AME Cloud Ventures Amgen Ventures +5 more

Biolinqbiolinq.com in

Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.

Digital HealthHardwareMedical Devices

Jared Tangney(Founder)inRich Yangin

Co-investorsAble Partners Alpha Wave Global Aphelion Capital Averin Capital Features Capital Holdings Hikma Ventures +3 more

Colossal Biosciencescolossal.com 𝕏

Capital Factory is an investment and advisory network that connects ambitious founders and operators with investors, advisors, and resources to support early-stage companies addressing significant challenges.

Deep TechSector AgnosticAustin, US

Ben Lamm(Founder)in Brian Beard(Executive Officer, Director)in

Board Tom Chi(Director)in

Co-investorsAt One Ventures Bold Capital Partners Breyer Capital Carnrite Ventures Draper Associates Evolution VC Partners +9 more

Fountain Lifefountainlife.com in

Fountain Life is a private preventive health membership service that uses AI-guided diagnostics, physician-led interpretation, and restorative therapeutics to detect issues early and create personalized plans focused on healthspan and longevity.

AI & Machine LearningDigital HealthHealthtechLongevityOrlando, US

Anthony Robbins(Director)Robert Hariri, MD(Director)Peter H. Diamandis, MD(Director)inWilliam K. Kapp, III, MD(Director)Dr. William Kapp(Co-Founder & CEO)

BoardDr. B.K. Modi(Director)

Co-investorsBold Capital Partners Eos Venture Partners Limited Seed Healthcare

Insilico Medicineboldcapitalpartners.com in 𝕏

This page is a thought-leadership essay by Teymour Boutros-Ghali of Bold Capital Partners arguing that venture investors and foundations should fund the commercialization phase of health-equity-focused life science companies using non-dilutive capital.

BiotechBaltimore, US

Aleksandrs Zavoronkovs(Executive Officer, Director)

Co-investorsB Capital Group Bold Capital Partners Harmonix Fund LongeVC SquareOne Capital

Insilico Medicineinsilico.com in 𝕏Sep 2019

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong

Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

BoardNisa Leung(Director)Lennart Lee(Director)

Co-investorsLilly Asia Ventures OrbiMed Qiming Venture Partners Warburg Pincus Baidu Ventures Eight Roads Ventures +9 more

Ouraouraring.com

Oura Ring is a wearable smart ring that collects and analyzes 50+ personal health metrics to provide insights on sleep, fitness, and wellness for individual users.

HardwareHealthtechWellness & FitnessSan Francisco, US

Ashley Colley(Founder)Virpi Tuomivaara(Founder)in Tom Hale(CEO)in

Co-investors125 Ventures A-Rod Corp Able Partners Alumni Ventures Basecamp Fund Bold Capital Partners +27 more

Propriopropriovision.com in 𝕏

Proprio develops Paradigm, an implant-agnostic surgical platform that provides intraoperative guidance and structured surgical data without requiring 3D imaging or mobile CT.

AI & Machine LearningHealthtechMedical DevicesSeattle, US

Gabriel Jones(Co-founder & CEO)in Samuel Browd(Co-founder)inJoshua Smith(Co-founder)inJames Youngquist(Co-founder)in

Co-investorsBold Capital Partners Cota Capital DCVC (Data Collective)Bird B. AG HTC Presence Capital +4 more

Verge Genomicsvergegenomics.com in 𝕏

Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US

Alice Zhang(Co-founder & CEO)inJason Chen(Cofounder)inEmily Ripka(Head of Product & Engineering)in

Co-investorsAgent Capital Draper Associates Fitz Gate Ventures Great Oaks Venture Capital Karlin Ventures Lifeforce Capital +5 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

4DMT

Exits · 1

1 IPOs

4D Molecular TherapeuticsNASDAQ: FDMT

Portfolio news

latest coverage across their companies

Colossal co-founder Ben Lamm raises $20M at $3.8B for AI that predicts how biology breaks — TFN

Colossal Biosciences · techfundingnews.com · Aug 21, 2026

Persistent Asset Partners Ltd Makes New $1.94 Million Investment in 4D Molecular Therapeutics, Inc. $FDMT

4D Molecular Therapeutics · marketbeat.com · Aug 17, 2026

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths | The Manila Times

Insilico Medicine · manilatimes.net · Aug 17, 2026

Insilico Medicine Included in MSCI Global Small Cap Indexes, Gaining Capital Market Endorsement in Core Strengths | The Manila Times

Insilico Medicine · manilatimes.net · Aug 17, 2026

Oura Secures Investment From Eli Lilly To Expand Connected Health Tools

Oura · pulse2.com · Jul 17, 2026

Fountain Life makes longevity accessible with $595 membership

Fountain Life · longevity.technology · Jul 3, 2026

Verge Genomics drops sole clinical candidate in return to AI drug discovery roots

Verge Genomics · fiercebiotech.com · Dec 18, 2025

FDA clears Biolinq's color-coded sensor patch for glucose ranges

Biolinq · fiercebiotech.com · Sep 29, 2025

Frequently asked questions

How many investments has BOLD Longevity made?: BOLD Longevity has 12 tracked investments, 1 of which have exited.
What stage does BOLD Longevity invest at?: BOLD Longevity invests at the Growth, Late Stage stages.
What sectors does BOLD Longevity focus on?: BOLD Longevity focuses on AI & Machine Learning, Biotech, Healthtech, Longevity.
Where is BOLD Longevity located?: BOLD Longevity is headquartered in Boston, US.
Does BOLD Longevity lead rounds?: BOLD Longevity typically participates in rounds rather than leading them.
Who does BOLD Longevity co-invest with?: BOLD Longevity most often shares deals with Bold Capital Partners, B Capital Group, Draper Associates, among 87 tracked co-investors.

Media · Podcasts & interviews

featuring the team

Mustafa Suleyman: The AGI Race Is Fake, Building Safe Superintelligence & the Agentic Economy | #216